Xilio Therapeutics Expands Authorized Shares at Annual Meeting

Xilio Therapeutics ( (XLO) ) has issued an announcement.

On June 10, 2025, Xilio Therapeutics held its annual stockholders meeting where several key decisions were made. René Russo, Pharm.D., Sara M. Bonstein, and James Shannon, M.D., were elected as Class I directors for a three-year term. Stockholders approved an amendment to increase the company’s authorized shares from 200 million to 600 million and another amendment regarding officer exculpation. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s operational capabilities and governance structure.

The most recent analyst rating on (XLO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.

Spark’s Take on XLO Stock

According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.

Xilio Therapeutics receives a moderate score due to a mix of promising strategic partnerships and ongoing financial challenges. The partnership with AbbVie is a notable positive, providing potential financial and strategic benefits. However, the company’s current lack of profitability and negative cash flow impact the overall evaluation. Technical analysis indicates short-term momentum, but longer-term trends remain a concern. The valuation reflects the company’s current unprofitability.

To see Spark’s full report on XLO stock, click here.

More about Xilio Therapeutics

Xilio Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of tumor-selective immuno-oncology therapies. The company aims to enhance the treatment of cancer by leveraging its proprietary technology to create therapies that target tumors while minimizing damage to healthy tissues.

Average Trading Volume: 1,249,892

Technical Sentiment Signal: Sell

Current Market Cap: $36.25M

For a thorough assessment of XLO stock, go to TipRanks’ Stock Analysis page.